MA14.03 EGFR M+ Subgroup of Phase 1b Study of Telisotuzumab Vedotin (Teliso-V) Plus Erlotinib in c-Met+ Non-Small Cell Lung Cancer
Publication
, Conference
Camidge, DR; Barlesi, F; Goldman, J; Morgensztern, D; Heist, R; Vokes, E; Spira, A; Angevin, E; Su, W; Hong, D; Strickler, J; Motwani, M ...
Published in: Journal of Thoracic Oncology
October 2019
Duke Scholars
Published In
Journal of Thoracic Oncology
DOI
ISSN
1556-0864
Publication Date
October 2019
Volume
14
Issue
10
Start / End Page
S305 / S306
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Camidge, D. R., Barlesi, F., Goldman, J., Morgensztern, D., Heist, R., Vokes, E., … Kelly, K. (2019). MA14.03 EGFR M+ Subgroup of Phase 1b Study of Telisotuzumab Vedotin (Teliso-V) Plus Erlotinib in c-Met+ Non-Small Cell Lung Cancer. In Journal of Thoracic Oncology (Vol. 14, pp. S305–S306). Elsevier BV. https://doi.org/10.1016/j.jtho.2019.08.612
Camidge, D. R., F. Barlesi, J. Goldman, D. Morgensztern, R. Heist, E. Vokes, A. Spira, et al. “MA14.03 EGFR M+ Subgroup of Phase 1b Study of Telisotuzumab Vedotin (Teliso-V) Plus Erlotinib in c-Met+ Non-Small Cell Lung Cancer.” In Journal of Thoracic Oncology, 14:S305–6. Elsevier BV, 2019. https://doi.org/10.1016/j.jtho.2019.08.612.
Camidge DR, Barlesi F, Goldman J, Morgensztern D, Heist R, Vokes E, et al. MA14.03 EGFR M+ Subgroup of Phase 1b Study of Telisotuzumab Vedotin (Teliso-V) Plus Erlotinib in c-Met+ Non-Small Cell Lung Cancer. In: Journal of Thoracic Oncology. Elsevier BV; 2019. p. S305–6.
Camidge, D. R., et al. “MA14.03 EGFR M+ Subgroup of Phase 1b Study of Telisotuzumab Vedotin (Teliso-V) Plus Erlotinib in c-Met+ Non-Small Cell Lung Cancer.” Journal of Thoracic Oncology, vol. 14, no. 10, Elsevier BV, 2019, pp. S305–06. Crossref, doi:10.1016/j.jtho.2019.08.612.
Camidge DR, Barlesi F, Goldman J, Morgensztern D, Heist R, Vokes E, Spira A, Angevin E, Su W, Hong D, Strickler J, Motwani M, Sun Z, Parikh A, Komarnitsky P, Wu J, Kelly K. MA14.03 EGFR M+ Subgroup of Phase 1b Study of Telisotuzumab Vedotin (Teliso-V) Plus Erlotinib in c-Met+ Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. Elsevier BV; 2019. p. S305–S306.
Published In
Journal of Thoracic Oncology
DOI
ISSN
1556-0864
Publication Date
October 2019
Volume
14
Issue
10
Start / End Page
S305 / S306
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology